Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.
about
Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?Donor antigen-primed regulatory T cells permit liver regeneration and phenotype correction in hemophilia A mouse by allogeneic bone marrow stem cells.Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs.Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice.Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience.Real-world resource use and costs of haemophilia A-related bleeding.Long-term results of ankle arthrodesis in children and adolescents with haemophilia.Outcome measures for adult and pediatric hemophilia patients with inhibitors.Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.Efmoroctocog Alfa: A Review in Haemophilia A.New therapies for hemophilia.Biomechanical markers and theoretical concepts related to haemophilic ankle and subtalar joint arthropathy: introducing the term 'haemophilic tarsal pan-arthropathy'.European retrospective study of real-life haemophilia treatment.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.Visualization of haemophilic arthropathy in F8-/- rats by ultrasonography and micro-computed tomography.The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors.The Haemophilia Joint Visualizer: development of a personalized, interactive, web-based tool to help improve adherence to prophylaxis.Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B.PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.Reliability and clinical features associated with the IPSG MRI tibiotalar and subtalar joint scores in children, adolescents and young adults with haemophilia.Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes.The F8(-/-) rat as a model of hemophilic arthropathy.An innovative outcome-based care and procurement model of hemophilia management.Bone Density Status in Bleeding Disorders: Where Are We and What Needs to Be Done?Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate® : Final report from a prospective study.Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker.Optimization of prophylaxis for hemophilia A.Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.Use of desmopressin in the treatment of hemophilia A: towards a golden jubilee.Validation of the Brazilian version of the VERITAS-Pro scale to assess adherence to prophylactic regimens in hemophilia.GlycoPEGylated recombinant factor IX for hemophilia B in context
P2860
Q28075208-7D129488-E2E4-46CD-AFF8-A4D170EDC5F9Q35885551-251BB0EA-97B8-424C-B380-9F07EEEF0DB0Q35969194-27E5E86C-F9ED-473F-AF62-D43AA245C593Q36644270-7B6077B3-D5F0-4531-BE7F-0BD5CF5BC1F1Q38652396-98A5F8C4-8EE6-49AD-80BA-E08A9F233AC5Q38675749-18C58D76-9104-45A8-8990-CCD0C7175BD0Q38829515-E3DA2B6D-C499-49AB-AB33-F6702A0DC35AQ38884504-442A6032-919A-4241-B5C6-D1B4314E2DF9Q38888065-86ECA6C2-CA9E-43B7-8B82-C086E015B14AQ38917306-07C59FA0-F6F6-42FE-9058-FC8142989CCBQ39027887-98FBCC9F-A6AF-4A6E-9F20-9A7DEBC3B564Q39183806-D6CB7BFD-1AB1-4012-AC5C-77CFE2A88079Q39268322-74F0E5EA-F70A-4B60-A157-36D0AD695B0CQ39475869-E849D7BF-F97A-4B36-AD0B-FB19E485DBE3Q45855101-0C48E961-EBBC-47FE-A8DD-EE30D3A73430Q45858124-72A94518-95EB-4D8D-84D2-7DB2F9C83AD6Q45862594-33ABF483-9794-47DC-B9D1-966DAEA40947Q45863022-00FDE922-5667-4BBE-98AD-03E7F4D4D797Q45863516-2D0C5D30-7CB7-4E72-8945-1750000768D5Q45863870-3A099896-B830-4AF4-8B29-EDC27E03DBD4Q45864807-C3463AA9-9044-46ED-AB80-A7011B376F00Q45868343-A45317D8-6C05-4EF5-A700-3CB9D71DA05FQ45870435-747B63DF-0964-48D7-A7E7-74906FF9EE18Q45871093-3D71779B-51C1-4AB9-ACD3-8E1F1F30D594Q45871324-5DDA02E0-1B94-4C2C-A4CD-190E660657D9Q45873262-05C837E3-D20D-4D1C-8E98-3933FEDA3C9CQ45873738-FCE0A95E-023B-4681-9618-ED329742CF40Q45874927-D2B7DC4B-9B27-492B-9566-41676DB17022Q45878869-A011A896-2BF2-4BCD-9B41-EDA00EDACA11Q45884841-6B265106-5505-4801-A433-FF0709521897Q45884983-D06488A9-B6CD-4BE5-8624-773787D65C9CQ47162354-A8707468-4DCF-4186-9347-D097BF360D45Q47556737-8DDFF3EF-7B07-404A-9EFE-310DCD9140CEQ48357830-0B115D69-6FB5-4EAB-B78B-D76C9E67E263Q49980032-68CE6775-27E1-4D93-BF2C-03D0C5785ABDQ50139622-DE8E0329-22CF-4ED1-BE0F-A40A0D5F31BFQ52744090-22324AEA-F0CE-456B-981E-DEAE9B3EBCE6Q55384072-945BD3BB-5D7B-445D-A484-A2C72CFFC471Q55389077-56D3EAC3-A547-43B1-A440-2BAD5729EBC4Q57158345-3985DE27-FBBC-4791-91DD-54E1249DEBB9
P2860
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Optimal treatment strategies f ...... current prophylactic regimens.
@en
type
label
Optimal treatment strategies f ...... current prophylactic regimens.
@en
prefLabel
Optimal treatment strategies f ...... current prophylactic regimens.
@en
P1433
P1476
Optimal treatment strategies f ...... current prophylactic regimens.
@en
P2093
Johannes Oldenburg
P304
P356
10.1182/BLOOD-2015-01-528414
P407
P577
2015-02-23T00:00:00Z